TY - JOUR T1 - Mathematical Model of a Personalized Neoantigen Cancer Vaccine and the Human Immune System: Evaluation of Efficacy JF - medRxiv DO - 10.1101/2021.01.08.21249452 SP - 2021.01.08.21249452 AU - Marisabel Rodriguez Messan AU - Osman N. Yogurtcu AU - Joseph R. McGill AU - Ujwani Nukala AU - Zuben E. Sauna AU - Hong Yang Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249452.abstract N2 - Cancer vaccines are an important component of the cancer immunotherapy toolkit, enhancing the immune response to malignant cells by activating CD4+ and CD8+ T-cells. Multiple successful clinical applications of cancer vaccines have shown good safety and efficacy. Despite the notable progress, significant challenges remain in obtaining consistent immune responses across heterogeneous patient populations, as well as various cancers. We present a mechanistic mathematical model describing key interactions of a personalized neoantigen cancer vaccine with the immune system of an individual patient. The model specifically considers the vaccine concentration of tumor-specific antigen peptides and adjuvant, patient’s major histocompatibility complexes I and II copy numbers, tumor size, T-cells, and antigen presenting cells. We calibrated the model using patient-specific data from a recent clinical study where individualized cancer vaccines were used to treat six melanoma patients. Model simulations predict both immune responses to the vaccine as well as clinical outcome. Our model has the potential to lay the foundation for generating in silico clinical trial data and aid the development and efficacy assessment of personalized cancer vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA ER -